PharmaCyte Biotech, Inc. Announces Reverse Stock Split
PharmaCyte Biotech, Inc. (PMCB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PharmaCyte Biotech, Inc. Announces Reverse Stock Split PharmaCyte’s common stock is expected to begin trading on a post-split adjusted basis on November 13, 2026 LAS VEGAS--(BUSINESS WIRE)—November 11, 2026—PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the
- Ratio
- 1-for-19
- Reverse split
- yes
- Effective
- November 12, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The reverse split is intended to lift the share price above the Nasdaq threshold, potentially stabilizing the stock and avoiding delisting.
Market read
Primary corporate action for a micro‑cap biotech; immediate relevance for shareholders and short‑term traders.
What to watch
Potential dilution from future equity raises or conversion of warrants could offset price benefits.
Background
PharmaCyte Biotech (PMCB) is a Nasdaq‑listed biotech whose share price has fallen below the $1 minimum bid requirement.
Ticker impact
Company announced a 1-for-19 reverse stock split to regain Nasdaq minimum bid price compliance.
likely upward pressure as the share price adjusts post‑split
Higher share price improves compliance and may lift market perception, but fundamentals unchanged.
Market effects
May set a precedent for other low‑price Nasdaq‑listed biotech firms seeking compliance.
Limited to U.S. small‑cap biotech segment.
Minimal global impact.
Counterpoint
Some investors may view the split as a cosmetic move without real value creation.
Key entities
- companyPharmaCyte Biotech, Inc.
Issuer of the reverse split.
- service_providerEquiniti Trust Company, LLC
Transfer agent handling certificate exchanges.
